CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. (CTMX) Stock Overview
Explore CytomX Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
754M
P/E Ratio
-43.80
EPS (TTM)
$0.30
ROE
-0.20%
CTMX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of CytomX Therapeutics, Inc. (CTMX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 43.94, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $6.87.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -43.80 and a market capitalization of 754M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.